A combined role of calcium channel blockers and angiotensin receptor blockers in stroke prevention

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 593-605

  Wang, Ji Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Angiotensin; Blood pressure; Calcium channel; Cerebrovascular; Hypertension; Stroke

Indexed keywords

AMLODIPINE; ATENOLOL; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; ENALAPRIL; EPROSARTAN; FOSINOPRIL; INDAPAMIDE; LISINOPRIL; LOSARTAN; NIFEDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PRIMARY PREVENTION; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; STROKE; AGED; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; MIDDLE AGED; PATHOPHYSIOLOGY; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION; MIDDLE AGED; PRIMARY PREVENTION; RECURRENCE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME;

EID: 70350517564     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s6203     Document Type: Review

References (98)

1. Meairs S, Wahlgren N, Dirnagl U, Lindvall O, Rothwell P, Baron JC, et al. Stroke research priorities for the next decade - a representative view of the European scientific community. Cerebrovasc Dis. 2006; 22(2-3):75-82.
2. WHO atlas of heart disease and stroke. http://www.who.int/ cardiovascular-diseases/en/cvd-atlas-15-burden-stroke.pdf. Accessed July 8, 2009.
3. Truelsen T, Piechowski-Jóźwiak B, Bonita R, Mathers C, Bogousslavsky J, Boysen G. Stroke incidence and prevalence in Europe: a review of available data. Eur J Neurol. 2006;13(6):581-598.
4. Paul SL, Srikanth VK, Thrift AG. The large and growing burden of stroke. Curr Drug Targets. 2007;8(7):786-793.
5. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, et al. American Heart Association; American Stroke Association Stroke Council. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113(24):e873-e923.
6. Di Tullio MR, Zwas DR, Sacco RL, Sciacca RR, Homma S. Left ventricular mass and geometry and the risk of ischemic stroke. Stroke. 2003;34(10):2380-2384.
7. Lüders S. Drug therapy for the secondary prevention of stroke in hypertensive patients: current issues and options. Drugs. 2007;67(7): 955-963.
8. Coull AJ, Lovett JK, Rothwell PM; Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ. 2004;328(7435):326.
9. Xu G, Liu X, Wu W, Zhang R, Yin Q. Recurrence after ischemic stroke in Chinese patients: impact of uncontrolled modifiable risk factors. Cerebrovasc Dis. 2007;23(2-3):117-120.
10. Singh RB, Suh IL, Singh VP, Chaithiraphan S, Laothavorn P, Sy RG, et al. Hypertension and stroke in Asia: prevalence, control and strategies in developing countries for prevention. J Hum Hypertens. 2000;14(10-11):749-763.
11. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349); 1903-1913.
12. Lawes CM, Vander Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371(9623):1513-1518.
13. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol. 2002;1(3):149-156.
14. Mancia G, Grassi G. Secondary prevention of stroke: old and new evidence. Aging Clin Exp Res. 2002;14(3):216-220.
15. Grassi G, Arenare F, Trevano FQ, Dell'Oro R, Mancia AG. Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials. Curr Hypertens Rep. 2007;9(4):299-304.
16. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358(9290): 1305-1315.
17. Lawes CM, Rodgers A, Bennett DA, Parag V, Suh I, Ueshima H, et al. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens. 2003;21(4):707-716.
18. Lawes CM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke: an overview of published reviews. Stroke. 2004;35(4): 1024-1033.
19. Gueyffier F, Boissel JP, Boutitie F, Pocock S, Coope J, Cutler, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data Analysis of ANtihypertensive intervention trials) project collaborators. Stroke. 1997;28(12):2557-2562.
20. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008;24(1):121-127.
21. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503-1510.
22. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-764.
23. Staessen JA, Thijs L, Fagard RH, Birkenhäger WH, Arabidze GG, Babeanu S, et al. Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. Hypertension. 1998;32(3):410-416.
24. Wang JG, Staessen JA, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med. 2000;160(2):211-220.
25. Lubsen J, Wagener G, Kirwan BA, de Brouwer S, Poole-Wilson PA; ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens. 2005;23(3):641-648.
26. Dowlatshahi D, Fang J, Kawaja M, Hakim A. Use of calcium channel blockers after stroke is not associated with poor outcome: a cohort from the registry of the Canadian stroke network. J Neurol. 2006;253(11):1478-1483.
27. Bangalore S, Messerli FH. A review of stroke in patients with hypertension and coronary artery disease: Focus on calcium channel blockers. Int J Clin Pract. 2006;60(10):1281-1286.
28. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003-2004 secondary prevention trials. Hypertens Res. 2005;28(5):385-407.
29. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46(2):386-392.
30. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
31. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, et al. ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005;366(9489):907-913.
32. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217-2225.
33. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981-2997.
34. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, et al. ALLHAT Collaborative Research Group. Clinical events in high-risk hypertensive patients randomily assigned to calcium channel blocker vs angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006;48(3):374-384.
35. Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers. A quantitative overview. Hypertension. 2007;50(1):181-188.
36. Iadecola C, Gorelick PB. Hypertension, angiotensin, and stroke: beyond blood pressure. Stroke. 2004;35(2):348-350.
37. Schrader J, Kulschewski A, Dendorfer A. Inhibition of the renin-angiotensin system and the prevention of stroke. Am J Cardiovasc Drugs. 2007;7(1):25-37.
38. Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, et al. HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002;324(7339):699-702.
39. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145-153.
40. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-1041.
41. Flather MD, Yusuf S, Koøber L, Pfeffer M, Hall A, Murray G, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355(9215):1575-1581.
42. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet. 1999;353(9153):611-616.
43. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A; CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta blocker-based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care. 2001;24(12):2091-2096.
44. Boutitie F, Oprisiu R, Achard JM, Mazouz H, Wang J, Messerli FH, et al. Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J Hypertens. 2007;25(8):1543-1553.
45. Epstein BJ, Gums JG. Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers. Pharmacotherapy. 2005;25(4):531-539.
46. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol. 2004;43(8):1343-1347.
47. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003.
48. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, et al. LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA. 2002;288(12):1491-1498.
49. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-719.
50. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875-886.
51. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174-1183.
52. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008;51(2):393-398.
53. ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-1559.
54. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26(7):1282-1289.
55. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke. 2003;34(7):1699-1703.
56. ClinicalTrials.gov [webpage]. Scandinavian Candesartan Acute Stroke Tirial (SCAST). [updated 2009 May 13; cited 2008 July 15]. Available from: http://clinicaltrials.gov/ct2/show/NCT00120003.
57. Schrader J , Lüder s S, Kul schewski A, Hammer sen F, Plate K, Berger J, et al. MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke. 2005;36(6):1218-1226.
58. Diener HC, Sacco R, Yusuf S; PRoFESS Study Group. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmis-artan vs placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis. 2007;23(5-6):368-380.
59. Yusuf S, Diener HC, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al. PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359(12):1225-1237.
60. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144(12):884-893.
61. Coca A, Messerli FH, Benetos A, Zhou Q, Champion A, Cooper-DeHoff RM, et al. Predicting stroke risk in hypertensive patients with coronary artery disease: a report from the INVEST. Stroke. 2008;39(2):343-348.
62. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet. 2004;363(9426):2049-2051.
63. Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, et al. PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24(6):1201-1208.
64. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, et al. Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571):1431-1439.
65. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-2031.
66. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA; VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26(3):403-411.
67. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527-1535.
68. Messerli FH, Staessen JA. Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies. Hypertension. 2006;48(3):359-361.
69. Thone-Reineke C, Krikov M, Schmerbach K, Muller S, Villringer A, Steckelings U, et al. Comparison of the effect of systematic pretreatment with telmisartan, ramipril and their combination on neurological status and infarct volume in rats after stroke. J Hypertens. 2008; 26(Suppl.1):S1.
70. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459-467.
71. Wang JG, Staessen JA, Li Y, Van Bortel LM, Nawrot T, Fagard R, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke. 2006;37(7): 1933-1940.
72. Mörtsell D, Malmqvist K, Held C, Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) study. J Intern Med. 2007;261(5):472-479.
73. Olsen MH, Wachtell K, Neland K, Bella JN, Rokkedal J, Dige-Petersen H, et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press. 2005;14(3):177-183.
74. Ono H, Minatoguchi S, Watanabe K, Yamada Y, Mizukusa T, Kawasaki H, et al. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res. 2008;31(2):271-279.
75. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension. 2003;41(2):218-223.
76. Sampson UK, Pfeffer MA, McMurray JJ, Lokhnygina Y, White HD, Solomon SD, et al. VALIANT Trial Investigators. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. Eur Heart J. 2007;28(6):685-691.
77. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation. 2003;108(6):711-716.
78. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003;115(1):41-46.
79. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-1225.
80. Lacy PS, Williams B. Impact of heart rate on the differential impact of blood pressure lowering drugs on central and peripheral pressures: Data from the Conduit Artery Function Evaluation (CAFÉ) study. J Hypertens. 2008;26(Suppl.1):S459.
81. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke. 2004;35(7):1726-1731.
82. Nishimura Y, Ito T, Saavedra JM. Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke. 2000;31(10):2478-2486.
83. Ito T, Yamakawa H, Bregonzio C, Terrón JA, Falcón-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke. 2002;33(9):2297-2303.
84. Kumai Y, Ooboshi H, Ago T, Ishikawa E, Takada J, Kamouchi M, et al. Protective effects of angiotensin II type 1 receptor blocker on cerebral circulation independent of blood pressure. Exp Neurol. 2008;210(2):441-448.
85. Mogi M, Iwai M, Chen R, Iwanami J, Ide A, Tsukuda K, et al. Amlodipine treatment reduces stroke size in apolipoprotein E-deficient mice. Am J Hypertens. 2006;19(11):1144-1149.
86. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The felodipine event reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23(12):2157-2172.
87. Jamerson KA, Bakris GL, Wun CC, Dahlöf B, Lefkowitz M, Manfreda S, et al. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens. 2004;17(9):793-801.
88. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.
89. Chalmers J, MacMahon S. Perindopril protection against recurrent stroke study (PROGRESS): interpretation and implementation. J Hypertens. 2003; 21(Suppl.):S9-S14.
90. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19): 2560-2572.
91. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6): 1105-1187.
92. Sica DA. Rationale for fixed-dose combination in the treatment of hypertension: the cycle repeats. Drugs. 2002;62(3):443-462.
93. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens. 2003;21(6):1055-1076.
94. Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS study. J Am Soc Hypertens. 2008;2:294-302.
95. Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29(4):563-580.
96. Smith TR, Philipp T, Vaisse B, Bakris GL, Wernsing M, Yen J, et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens. 2007;9(5):355-364.
97. Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007;29(2):279-289.
98. Brixner DI, Jackson KC 2nd, Sheng X, Nelson RE, Keskinaslan A. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free-and fixed-dose combinations. Curr Med Res Opin. 2008;24(9):2597-2607.